Diagnostics are focused on identifying patients for treatment much earlier, before CRAB features ... defined multiple myeloma with ≥60% BMPCs and an FLC ratio ≥100, TTP was extended by a ...

In the past, you had to have organ damage, as shown by CRAB criteria, to be diagnosed with multiple myeloma. CRAB is an acronym that stands for the signs on blood tests and imaging your doctor ...

CRAB criteria includes 11: These medical advances allow several hundred thousand to millions of bone marrow cells to be examined for the presence of residual multiple myeloma cells ... plans to travel ...

The blood cancer multiple myeloma, which involves infection-fighting plasma cells in the bone marrow, affects only about 1% of all cancers -- predominantly individuals over age 65. The disease ...

A healthcare provider or oncologist (who specializes in cancer) can diagnose multiple myeloma. They'll likely ask questions about your health history and symptoms. The "CRAB" criteria may indicate ...

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma ...

Daratumumab significantly reduced progression risk in smoldering multiple myeloma ... was measured using International Myeloma Working Group SLiM and CRAB criteria. At 5 years, 63.1% of patients ...

Smoldering multiple myeloma is an asymptomatic ... marrow plasma cells (BMPCs), but with no evidence of myeloma-related symptomatology (hypercalcemia, renal insufficiency, anemia, or bone lesions ...

Multiple myeloma is a malignancy of terminally differentiated plasma cells, and patients typically present with bone marrow infiltration of clonal plasma cells and monoclonal protein in the serum ...

Doctors use the acronym CRAB as a shorthand to describe the criteria they’re looking at: Multiple myeloma that does not cause these symptoms is called smoldering multiple myeloma (SMM).